Raymond Hill, a former licensing executive at Merck Sharp and Dohme, has joined the board of directors of Switzerland-based Asceneuron SA, which is developing small molecule therapeutics for neurodegenerative diseases. Professor Hill is a visiting professor at Imperial College, London and was elected as a fellow of the Academy of Medical Sciences in 2005.
Concurrently Asceneuron appointed Franz Hefti as a special advisor to the board. Dr Hefti was formerly chief scientific officer of Avid Radiopharmaceuticals before its acquisition by Eli Lilly and Company in 2010.
Asceneuron announced the appointments on 11 December 2014.
Copyright 2014 Evernow Publishing Ltd